Clinical Trial Update: Efficacy, Safety and Pharmacokinetic Study of Inhaled Esketamine in Treatment-resistant Bipolar Depression [Phase 2]

View source ↗

Summary

Phase 2 study assessing efficacy, safety, and pharmacokinetics of inhaled esketamine for treatment-resistant bipolar depression has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bipolar Depression

Drugs mentioned

• Esketamine (esketamine)

Snippet

Sponsor: Celon Pharma SA | Conditions: Bipolar Depression | Phase 2 | Status: COMPLETED